New drugs are not enough-drug repositioning in oncology: An update

被引:64
|
作者
Armando, Romina Gabriela [1 ]
Gomez, Diego Luis Mengual [1 ]
Gomez, Daniel Eduardo [1 ]
机构
[1] Natl Univ Quilmes, Sci & Technol Dept, Lab Mol Oncol, Roque Saenz Pena 352,B1876, Bernal, Argentina
关键词
drug; repositioning; repurposing; oncology; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HIV PROTEASE INHIBITORS; CANCER STEM-CELLS; PHOSPHODIESTERASE TYPE 5; HUMAN PROSTATE-CANCER; PHASE-II TRIAL; OVEREXPRESSING TISSUE INHIBITOR; MYELOID-LEUKEMIA MECHANISMS; CALCIUM-CHANNEL ANTAGONISTS; ENDOTHELIAL GROWTH-FACTOR;
D O I
10.3892/ijo.2020.4966
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that are already known for use treating other diseases. The advantages of this are that several important drug characteristics are already established (including efficacy, pharmacokinetics, pharmacodynamics and toxicity), making the process of research for a putative drug quicker and less costly. Drug repositioning in oncology has received extensive focus. The present review summarizes the most prominent examples of drug repositioning for the treatment of cancer, taking into consideration their primary use, proposed anticancer mechanisms and current development status.
引用
收藏
页码:651 / 684
页数:34
相关论文
共 50 条
  • [41] An update on therapeutic drug monitoring for antiretroviral drugs
    Back, David
    Gibbons, Sara
    Khoo, Saye
    THERAPEUTIC DRUG MONITORING, 2006, 28 (03) : 468 - 473
  • [42] New Urologic Oncology Drugs and The New Toxicities
    Gomella, Leonard G.
    CANADIAN JOURNAL OF UROLOGY, 2017, 24 (06) : 9075 - 9075
  • [43] In silico drug repositioning of FDA-approved drugs to predict new inhibitors for alpha-synuclein aggregation
    Jafaripour, Sedighe Sadat
    Gharaghani, Sajjad
    Nazarshodeh, Elmira
    Haider, Shozeb
    Saboury, Ali Akbar
    COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2020, 88
  • [44] Otorhinolaryngological Toxicities of New Drugs in Oncology
    Dana M. Hartl
    Daphné Morel
    Erika Saavedra
    Christophe Massard
    Alessandra Rinaldo
    Nabil F. Saba
    Alfio Ferlito
    Jean-Charles Soria
    Advances in Therapy, 2017, 34 : 866 - 894
  • [45] Market uptake of new oncology drugs
    Jonsson, B.
    Wilking, N.
    ANNALS OF ONCOLOGY, 2007, 18 : 31 - 48
  • [46] Technology Assessment for New Oncology Drugs
    Jonsson, Bengt
    CLINICAL CANCER RESEARCH, 2013, 19 (01) : 6 - 11
  • [47] FDA approves new oncology drugs
    不详
    CANCER PRACTICE, 1999, 7 (06) : 276 - 276
  • [48] New drugs in oncology and skin toxicity
    Mateus, C.
    Robert, C.
    REVUE DE MEDECINE INTERNE, 2009, 30 (05): : 401 - 410
  • [49] New drug approvals in oncology
    Kurzrock, Razelle
    Kantarjian, Hagop M.
    Kesselheim, Aaron S.
    Sigal, Ellen V.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (03) : 140 - 146
  • [50] Otorhinolaryngological Toxicities of New Drugs in Oncology
    Hartl, Dana M.
    Morel, Daphne
    Saavedra, Erika
    Massard, Christophe
    Rinaldo, Alessandra
    Saba, Nabil F.
    Ferlito, Alfio
    Soria, Jean-Charles
    ADVANCES IN THERAPY, 2017, 34 (04) : 866 - 894